Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
23.88
-0.32 (-1.32%)
Feb 11, 2026, 9:40 AM EST - Market open
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,294 employees as of December 31, 2024. The number of employees increased by 18 or 1.41% compared to the previous year.
Employees
1,294
Change (1Y)
18
Growth (1Y)
1.41%
Revenue / Employee
$487,325
Profits / Employee
-$448,090
Market Cap
2.30B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | 893 | 153 | 20.68% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptive Biotechnologies | 619 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Wave Life Sciences | 288 |
| Harmony Biosciences Holdings | 268 |
| Soleno Therapeutics | 152 |
| Mesoblast | 81 |
| Dianthus Therapeutics | 78 |
RARE News
- 1 day ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical - Newsfile Corp
- 2 days ago - RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit - PRNewsWire
- 8 days ago - Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) - GlobeNewsWire
- 12 days ago - Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA - GlobeNewsWire
- 18 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies - PRNewsWire
- 20 days ago - Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline - Seeking Alpha
- 4 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha